Multiple myeloma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BCMA 134
• CD38 22
• GPRC5D 36
• CD19 31
• TP53 0
• STAT3 0
• CXCR4 4
• MYC 0
• BCL-2 2
• PI3K 1
• mTOR 0
• IL-6 0
• STING 0
• BRAF 2
• CD47 1
• HDAC 0
• AKT 0
• PD-1 1
• PD-L1 1
• CD20 3
• GLP-1 0
• JAK 0
• PTEN 0
• SGLT2 0
• AMPK 0
• B7-H3 0
• NRAS 1
• TIGIT 0
• CTLA-4 1
• ERK 0
• EZH2 0
• FTO 0
• IL-15 3
• JNK 0
• KRAS 1
• MAPK 0
• RAS 0
• CD22 2
• CD33 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• LAG-3 0
• MDM2 0
• METTL3 0
• NRF2 0
• BRCA1 0
• BRD4 0
• BTK 1
• CD123 1
• CD30 0
• CDK4/6 0
• GPX4 0
• HER2 0
• HIF-1 0
• HSP90 0
• MEK 0
• MET 0
• MUC1 0
• NTRK 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Italy· EU contribution €193,643· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Sweden· EU contribution €2,000,000· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Microbiome-Driven Modulation of Immune Reconstitution and Vaccine Responsiveness in Multiple Myeloma Patients following Stem Cell Transplantation (MicroMM)

  Technische Universitaet Muenchen· Muenchen, Germany· EU contribution €1,466,571· until Oct 2031

• European Commission (Horizon Europe) · HORIZON-RIA

  iNK Cell–Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY (iN-KEY)

  Banc de Sang I Teixits· Barcelona, Spain· EU contribution €9,998,178· until Sept 2031· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A CEllulaR immunoTherapy virtuAl twin for personalIsed cancer treatmeNT (CERTAINTY)

  Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev· Munchen, Germany· EU contribution €9,999,253· until May 2028· 8 countries

5 of 7 running projects, newest first. Listed amounts together: €35.6m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 3
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 8
• Gene Expression Profiling 44
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Exome Sequencing 3
• Proteomics 15
• Metabolomics 10
• Mass Spectrometry 7
• Flow Cytometry 48
• Immunohistochemistry 11
• Liquid Biopsy 2
• Circulating Tumor DNA 2
• Xenograft Model Antitumor Assays 78
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 26
• Machine Learning 17
• Deep Learning 6
• Cohort Studies 32
• Genome-Wide Association Study 7

• Genomics-Guided Risk Stratification in Myeloma Precursor Conditions: Converging Frameworks From Whole-Genome Sequencing.

  Technol Cancer Res Treat, Nov 2026

• Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

  Clin Epigenetics, Apr 2026

• Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing.

  Blood Adv, Feb 2026

• Medical Cannabis as the Source of Cryptococcus neoformans Infection.

  Clin Infect Dis, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.